TroFuse-021/ENGOT-ov85/GOG-3102 A phase 3, Randomized, Open label, Multicentred Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HDR-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy